Published on 9 Jan 2023 on Benzinga via Yahoo Finance

Ocugen Announces Encouraging Data From Late-Stage COVID-19 Vaccine Study

Ocugen Inc (NASDAQ: OCGN) announced results from the Phase 2/3 study of its COVID-19 vaccine candidate, COVAXIN.COVAXIN has been demonstrated in clinical trials to generate a broader immune response against the whole virus covering important antigens such as S-protein, RBD, and N-protein, whereas currently approved vaccines in the U.S. target only S-protein antigens.In contrast to other inactivated vaccines, trials have demonstrated that TLR7/8 agonist adjuvant in COVAXIN generates a Th1-biased immune response that induces robust long-term memory B- and T-cell responses.Related: Ocugen Inks US Development Pact For Its Intranasal COVID-19 Vaccine.Both co-primary immunogenicity endpoints were met well above the non-inferiority limit with robust immune responses.Covaxin was found to be well-tolerated in vaccine-naïve individuals and individuals previously vaccinated with mRNA vaccines in the U.S., with no vaccine-related serious adverse events, thrombotic events, or cases of myocarditis or pericarditis.Price Action: OCGN shares are up 20.8% at $1.57 during the premarket session on the last check Monday.

See more from Benzinga